Hydralazine Injection Rx
Generic Name and Formulations:
Hydralazine (as HCl) 20mg/mL; IM or IV inj; contains parabens.
Various generic manufacturers
Indications for Hydralazine Injection:
Severe essential hypertension when oral therapy not feasible or there is an urgent need to lower blood pressure.
Monitor BP closely. 20–40mg; repeat as needed. Advanced renal damage: reduce dose.
Not recommended; doses of 1.7–3.5mg/kg per day in 4–6 divided doses have been used.
Coronary artery disease. Mitral valve disease.
Suspected coronary artery disease. Cerebrovascular accidents. Aortic aneurysm. Increased intracranial pressure. Renal disease. Treat paresthesias and/or numbness with pyridoxine. Discontinue if blood dyscrasias occur. Obtain CBC and ANA titer periodically; consider discontinuing if SLE occurs. Surgery. Pregnancy (Cat.C). Nursing mothers.
Caution with MAOIs. Profound hypotension with potent parenteral antihypertensives (eg, diazoxide). Antagonized by NSAIDs. May block epinephrine.
Headache, anorexia, GI disturbances, palpitations, edema, flushing, nasal congestion, lacrimation, rash, tachycardia, angina, orthostatic hypotension, blood dyscrasias, peripheral neuritis, SLE.
Formerly known under the brand names Apresoline (inj, tabs); Dralzine (tabs).
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States